Precise Biometrics: All eyes on commercialisation - ABG
Q3 report due Friday, 11 November We reduce ’23e-’24e sales by 3-1% Balance sheet set for growth after share issues
ANNONS
Q3’22 expectations
We decrease our Q3’22 sales estimates by 4% due to uncertainties regarding global semiconductor demand. Consequently, our EBITDA estimates are cut by 14% because of the company’s operating leverage. As a result of the recent SEK 44m share issues, the balance sheet will be well-suited for any potential downturn and ready for growth.
